Do Allergy Shots Help Asthma? Only for Allergic Asthma — Here Is Why

Only allergic asthma — also called IgE-mediated or atopic asthma — responds to allergy shots. This phenotype is characterized by positive allergy tests (skin prick test or specific IgE blood test) to relevant aeroallergens, often co-occurring with allergic rhinitis, typically early-onset (childhood or young adulthood), and symptom worsening with allergen exposure. Non-allergic asthma (triggered by cold air, exercise, irritants, or infections without IgE sensitization), late-onset eosinophilic asthma, and occupational asthma from non-allergen exposures do not respond to SCIT. A board-certified allergist can determine your asthma phenotype through testing and history before recommending immunotherapy.

SCIT is safe for patients with well-controlled asthma — specifically, those with FEV1 (forced expiratory volume in 1 second) of 70% predicted or better before each injection. The AAAAI/ACAAI Practice Parameter (Cox 2011) and GINA guidelines both specify that each allergy shot visit must include asthma assessment, with injections withheld if FEV1 falls below 70% or if active wheezing is present. Uncontrolled asthma is the dominant risk factor for fatal allergy shot reactions — accounting for the majority of fatalities in the AAAAI/ACAAI surveillance data (Bernstein 2004). Patients with severe persistent asthma, FEV1 consistently below 70%, or asthma requiring frequent systemic corticosteroids should not receive SCIT; biologics are more appropriate.

Yes — the strongest evidence for this comes from the PAT (Preventive Allergy Treatment) study by Moller et al. (JACI 2002), which randomized 205 children aged 6 to 14 with grass or birch pollen rhinitis. Children receiving 3 years of SCIT had significantly lower rates of asthma development versus untreated controls, with an odds ratio of 0.29 — meaning about 71% lower odds of developing asthma. This protective effect persisted at 5-year follow-up (Niggemann et al.) and 10-year follow-up (Jacobsen et al., Allergy 2007), where 25% of treated children had developed asthma compared to 45% of controls. Translating to practical terms: treating approximately 5 to 6 children with SCIT prevents one additional case of asthma.

Allergy shots improve asthma symptom scores and medication use consistently, but the effect on lung function measured by FEV1 is more variable and less consistent across trials. The Abramson Cochrane review (2010, 88 RCTs) found no consistent FEV1 improvement across the full analysis. However, in the HDM-monosensitized asthma subgroup, Zheng et al. (Front Pediatr 2023) found a significant improvement of +5.37% predicted FEV1 — a clinically meaningful change. Bronchial hyperreactivity, measured by methacholine challenge, does improve significantly with SCIT in most studies, indicating reduced airway sensitivity even when absolute FEV1 numbers are not dramatically changed. For most patients, the greatest functional benefit is in reduced exacerbations and reduced rescue medication use.

Yes — reducing rescue and controller medication use is a consistent and clinically important benefit of allergy shots in allergic asthma patients. The Abramson Cochrane review (2010) found significant medication score reduction (SMD -1.21 for dust mite asthma) alongside symptom score improvement. In real-world practice, many patients who complete SCIT are able to step down inhaled corticosteroid dosing, reduce rescue bronchodilator use, and in some cases eliminate controller medications entirely. This medication reduction has both quality-of-life and economic value — fewer medication side effects, lower ongoing pharmacy costs, and greater sense of disease control without daily dependence on multiple inhaled therapies.

The PAT (Preventive Allergy Treatment) study is the landmark clinical trial establishing that allergy shots can prevent asthma from developing in allergic children. Published by Moller et al. in JACI 2002 and followed up by Niggemann (2006) and Jacobsen (2007), the PAT study randomized 205 children aged 6 to 14 with grass or birch pollen allergic rhinoconjunctivitis to 3 years of SCIT versus open control. At 10-year follow-up — 7 years after stopping SCIT — 25% of treated children had developed asthma compared to 45% of controls. This sustained asthma prevention effect, persisting years after stopping treatment, is one of the strongest arguments that SCIT is genuinely disease-modifying and not just symptom-suppressing.